Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

BEVA issues warning about unvalidated genetic tests
"We encourage owners to speak with their vets about the evidence basis for decision making when investigating myopathies in horses." - Professor Piercy
The unvalidated genetic tests check for certain myopathies in horses.

Horse owners are being strongly advised against the use of independent and unvalidated genetic tests for certain myopathies. The warning comes from the British Equine Veterinary Association (BEVA), that says the practice has become widespread within some breed groups, despite the lack of evidence to support the tests.

The genetic tests, check for myopathies including diseases known as type 2 polysaccharide storage myopathy (PSSM2), myofibrillar myopathy (MFM) or muscle integrity myopathy (MIM). 

Professor Richard Piercy from the Royal Veterinary College said: “Scientists still do not know whether these are diseases at all, or whether they reflect histopathological features of non-specific muscle damage that might have various genetic but also environmental causes.

“It can of course be very tempting for a horse owner, when their horse has signs that might suggest a muscle problem, to seek any answer they can find, particularly when the problem is proving challenging to diagnose and manage. 

“It might be even more tempting for an owner to believe an unsubstantiated genetic result when it ‘fits’ with what they have suspected. But given the high prevalence of the genetic variants in the horse population that are tested for, many horses will test positive just by chance – whether or not they have any disease at all.”

Type one PSSM can be diagnosed by DNA testing of a mutation that has been robustly evaluated, but the current advice is to use clinical examination, biochemical testing and muscle biopsy, to identify myopathies in horses.

BEVA does not recommend scientifically unvalidated genetic tests that are offered by companies in Europe and the USA, for diagnosis of equine muscle diseases including PSSM2, MFM and MIM. 

Professor Piercy continued: “We encourage owners to speak with their vets about the evidence basis for decision making when investigating myopathies in horses.

“Until results of genetic testing for PSSM2, MFM, MIM and other myopathies in horses are presented in peer reviewed, validated scientific literature that is accepted by the scientific community (as has been the case for PSSM1), we do not recommend their use and certainly do not support veterinary or life decisions being made based on their results.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.